Nexthera Capital
Latest statistics and disclosures from Nexthera Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are Intercept Pharmaceuticals In, INSM, Audentes Therapeutics, NBIX, SRPT, and represent 42.28% of Nexthera Capital's stock portfolio.
- Added to shares of these 10 stocks: Intercept Pharmaceuticals In (+$11M), CHRS (+$7.0M), ASND (+$6.9M), PCRX (+$6.5M), NBIX (+$5.8M), INSM, SRPT, ABBV, Biohaven Pharmaceutical Holding, Global Blood Therapeutics In.
- Started 11 new stock positions in ITCI, Dermira, ANAB, REGN, ASND, Mylan Nv, PCRX, ABBV, Biohaven Pharmaceutical Holding, CHRS. GILD.
- Reduced shares in these 10 stocks: HRTX (-$9.5M), BHC (-$5.1M), , , Cymabay Therapeutics, , , Allergan, Kiniksa Pharmaceuticals, Chiasma.
- Sold out of its positions in Acorda Therapeutics, BHC, BMRN, Chiasma, Cymabay Therapeutics, Deciphera Pharmaceuticals, EXEL, HRTX, NVS, SAGE. D Stemline Therapeutics, Kiniksa Pharmaceuticals.
- Nexthera Capital was a net buyer of stock by $40M.
- Nexthera Capital has $120M in assets under management (AUM), dropping by 45.71%.
- Central Index Key (CIK): 0001646343
Tip: Access up to 7 years of quarterly data
Positions held by Nexthera Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Nexthera Capital
Nexthera Capital holds 23 positions in its portfolio as reported in the June 2019 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Intercept Pharmaceuticals In | 10.1 | $12M | +1175% | 152k | 79.57 |
|
| Insmed (INSM) | 10.0 | $12M | +65% | 471k | 25.60 |
|
| Audentes Therapeutics | 9.3 | $11M | +17% | 294k | 37.86 |
|
| Neurocrine Biosciences (NBIX) | 6.5 | $7.8M | +284% | 92k | 84.43 |
|
| Sarepta Therapeutics (SRPT) | 6.4 | $7.6M | +136% | 50k | 151.96 |
|
| Global Blood Therapeutics In | 6.2 | $7.5M | +63% | 142k | 52.60 |
|
| Immunomedics | 6.0 | $7.3M | +56% | 524k | 13.87 |
|
| Coherus Biosciences (CHRS) | 5.8 | $7.0M | NEW | 316k | 22.10 |
|
| Ascendis Pharma A S (ASND) | 5.8 | $6.9M | NEW | 60k | 115.16 |
|
| Pacira Pharmaceuticals (PCRX) | 5.4 | $6.5M | NEW | 149k | 43.49 |
|
| Urogen Pharma (URGN) | 5.3 | $6.4M | +33% | 177k | 35.94 |
|
| Uniqure Nv (QURE) | 3.9 | $4.7M | +54% | 60k | 78.15 |
|
| Amarin Corporation | 3.7 | $4.5M | +54% | 230k | 19.39 |
|
| Abbvie (ABBV) | 3.2 | $3.8M | NEW | 53k | 72.72 |
|
| Biohaven Pharmaceutical Holding | 3.1 | $3.8M | NEW | 86k | 43.79 |
|
| Mylan Nv | 1.6 | $2.0M | NEW | 103k | 19.04 |
|
| Intra Cellular Therapies (ITCI) | 1.6 | $1.9M | NEW | 144k | 12.98 |
|
| Regeneron Pharmaceuticals (REGN) | 1.5 | $1.8M | NEW | 5.7k | 312.99 |
|
| Madrigal Pharmaceuticals (MDGL) | 1.4 | $1.6M | +346% | 15k | 104.78 |
|
| Dermira | 1.1 | $1.3M | NEW | 138k | 9.56 |
|
| Gilead Sciences (GILD) | 1.1 | $1.3M | NEW | 19k | 67.55 |
|
| Anaptysbio Inc Common (ANAB) | 0.6 | $679k | NEW | 12k | 56.46 |
|
| Allergan | 0.5 | $560k | -75% | 3.3k | 167.31 |
|
Past Filings by Nexthera Capital
SEC 13F filings are viewable for Nexthera Capital going back to 2015
- Nexthera Capital 2019 Q2 filed Aug. 14, 2019
- Nexthera Capital 2019 Q1 filed May 15, 2019
- Nexthera Capital 2018 Q4 filed Feb. 14, 2019
- Nexthera Capital 2018 Q3 filed Nov. 14, 2018
- Nexthera Capital 2018 Q2 filed Aug. 14, 2018
- Nexthera Capital 2018 Q1 filed May 15, 2018
- Nexthera Capital 2017 Q4 filed Feb. 14, 2018
- Nexthera Capital 2017 Q3 filed Nov. 14, 2017
- Nexthera Capital 2017 Q2 filed Aug. 14, 2017
- Nexthera Capital 2017 Q1 filed May 15, 2017
- Nexthera Capital 2016 Q4 filed Feb. 14, 2017
- Nexthera Capital 2016 Q3 filed Nov. 14, 2016
- Nexthera Capital 2016 Q2 filed Aug. 15, 2016
- Nexthera Capital 2016 Q1 filed May 13, 2016
- Nexthera Capital 2015 Q4 filed Feb. 16, 2016